Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Lyndra Therapeutics on the deal. Lyndra Therapeutics, a developer of orally administered steady-state release pills, announced its $60.5...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here